Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | QRFPR | Q96P65 | 5/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361988 | 0.93 | FOLH1 (0.49) | FOLH1RIMKLANAALAD2GNPATGLO1 | |
| SCHEMBL8361982 | 0.93 | FOLH1 (0.49) | FOLH1RIMKLANAALAD2GNPATGLO1 | |
| SCHEMBL31522798 | 0.92 | FOLH1 (0.43) | FOLH1RIMKLANAALAD2QRFPRNMT2 | |
| SCHEMBL30496531 | 0.92 | FOLH1 (0.43) | FOLH1RIMKLANAALAD2QRFPRNMT2 | |
| SCHEMBL30261857 | 0.92 | FOLH1 (0.47) | FOLH1RIMKLANAALAD2GNPATGLO1 | |
| SCHEMBL29539031 | 0.91 | QRFPR (0.43) | QRFPRNMT2NMT1TGFBR1BMP1 | |
| SCHEMBL30261878 | 0.90 | FOLH1 (0.47) | FOLH1RIMKLANAALAD2QRFPRNMT2 | |
| SCHEMBL31479983 | 0.90 | FOLH1 (0.43) | FOLH1RIMKLANAALAD2QRFPRNMT2 | |
| SCHEMBL30139569 | 0.89 | FOLH1 (0.45) | FOLH1RIMKLANAALAD2QRFPRNMT2 | |
| SCHEMBL29824218 | 0.89 | FOLH1 (0.45) | FOLH1RIMKLANAALAD2QRFPRNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| US-11344548-B2 | Analogs of 3,5-dihydroxypentanoate for bone formation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2022-05-31 | — | — | US | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344548-B2 | Analogs of 3,5-dihydroxypentanoate for bone formation | CYP24A1, CYP27B1, CYP2R1 | FOLH1 1578/4885RIMKLA 1215/4885NAALAD2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.